Japan to spend $1.2 billion for 1.6 million courses of Merck's COVID-19 pill

2021-11-10 14:13:55

Molnupiravir, Merck's COVID-19 pill.

Asian Tech Press (Nov 10) -- The Japanese government will reportedly spend nearly $1.2 billion for 1.6 million courses of Merck's COVID-19 pill.

Reuters reported that the US drug company Merck Sharp & Dohme Corp. (MSD) and its partner Ridgeback Biotherapeutics LP said on Wednesday that the Japanese government would pay nearly $1.2 billion for 1.6 million courses of molnupiravir, a new oral antiviral medicine for COVID-19 it is co-developing, if it is approved.

MSD expects to produce 10 million courses of molnupiravir by the end of 2021 and at least 20 million courses in 2022.

The report also mentioned that the U.S. government has pledged on Tuesday to buy an additional $1 billion worth of molnupiravir.

COVID-19 pill Merck Japan

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.
                            2025-01-31

                                    White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.
                            2025-02-01

                                    Apple (AAPL.O) said the Apple Pay outage has been resolved.
                            2025-01-29

                                    Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.
                            2025-01-30

                                    Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.
                            2025-02-03